Aarti Pharma Labs

Aarti Pharma Labs

939.50
+13.15
(1.42%)
Market Cap
8,515.12 Cr
EPS
30.06
PE Ratio
31.52
Dividend Yield
0.54 %
Industry
Healthcare
52 Week High
971.00
52 Week Low
557.05
PB Ratio
4.22
Debt to Equity
0.19
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
positive
Aarti Pharmalabs Sets Record Date for ₹2.5 Final Dividend PaymentAug 19, 2025
Aarti Pharmalabs Limited has established September 15, 2025 as the record date for final dividend payment of ₹2.5 per equity share for financial year 2024-25. The dividend represents 50% of the face value of ₹5 per share and requires shareholder approval at the Annual General Meeting scheduled for September 22, 2025. Payment will be made to shareholders whose names appear in the company's register on the record date, with distribution expected on or before October 20, 2025.
positive
Aarti Pharmalabs Reports Q1 FY2026 Results, Appoints New Auditors and Re-appoints Independent DirectorAug 12, 2025
Aarti Pharmalabs Limited announced its unaudited financial results for Q1 FY2026 ended June 30, 2025. On a standalone basis, the company reported revenue from operations of Rs. 37,531.06 lakhs and net profit of Rs. 5,122.08 lakhs, with basic earnings per share of Rs. 5.65. On a consolidated basis, revenue from operations was Rs. 38,619.09 lakhs with net profit of Rs. 4,950.12 lakhs and basic EPS of Rs. 5.46. The board also approved the appointment of M/s Mehta & Mehta as secretarial auditors for five consecutive years starting FY 2025-26, subject to AGM approval. Additionally, the board approved the re-appointment of Ms. Rupal Vora as Non-executive Independent Director for a second term of three years from October 17, 2025 to October 16, 2028, pending shareholder approval. The company also approved extending its stock option scheme to eligible directors and employees of subsidiary companies.
positive
Aarti Pharmalabs Reports Strong Q3 Results and Declares DividendFeb 06, 2025
Aarti Pharmalabs announced its Q3 consolidated net profit of 740 million rupees, showing significant growth compared to 528 million rupees year-over-year and 546 million rupees quarter-over-quarter. The company's Q3 revenue increased to 5.4 billion rupees from 4.48 billion rupees in the previous year. Additionally, Aarti Pharmalabs declared a dividend of 2.5 rupees per equity share.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,602.00
#1 3,84,373.46
33.81
#1 54,729.00
9.71
#1 10,980
-19.84
50.98
6,057.00
1,60,794.32
69.37
9,712.00
18.67
2,191
26.74
40.39
1,548.30
1,25,057.40
23.57
28,409.50
7.12
5,291
9.88
56.04
3,531.60
1,19,525.39
59.77
11,539.40
6.99
1,911
19.91
46.48
1,300.80
1,08,561.01
#1 19.34
33,741.20
16.73
5,725
1.26
63.19
2,585.40
1,06,706.89
56.33
12,744.20
#1 20.90
2,007
-18.14
55.08
1,036.90
1,04,336.40
22.55
23,511.00
18.55
4,615
2.60
68.47
2,046.00
93,439.89
25.22
22,909.50
13.74
3,306
#1 51.64
67.14
5,500.50
65,766.73
28.64
13,458.30
3.70
2,216
21.39
67.21
30,910.00
65,681.59
45.31
6,684.70
9.64
1,414
11.55
39.45
Forecast
Actual
Growth Rate
Revenue Growth
-4.63 %
Net Income Growth
12.09 %
Cash Flow Change
53.25 %
ROE
-0.64 %
ROCE
-1.87 %
EBITDA Margin (Avg.)
19.06 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
463
457
532
472
486
459
441
450
508
558
463
543
562
388
Expenses
385
371
441
385
405
374
352
353
388
459
364
409
418
293
EBITDA
78
86
91
87
81
85
89
97
120
99
98
134
144
95
Operating Profit %
16 %
19 %
17 %
18 %
16 %
19 %
20 %
21 %
23 %
17 %
20 %
24 %
26 %
24 %
Depreciation
14
14
17
16
16
17
18
19
19
20
21
23
23
23
Interest
5
4
6
5
6
4
4
5
5
5
6
10
7
7
Profit Before Tax
60
68
69
65
59
64
67
74
96
74
72
101
115
65
Tax
11
16
18
17
16
17
15
21
31
18
17
27
26
16
Net Profit
49
52
51
48
43
47
52
53
65
56
55
74
88
50
EPS in ₹
5.39
5.72
5.64
5.26
4.73
5.20
5.72
5.82
7.20
6.12
6.03
8.16
9.75
5.46

Balance Sheet

Balance Sheet
2021
2022
2023
2024
2025
Total Assets
0
2,040
2,244
2,582
2,906
Fixed Assets
0
782
926
1,033
1,137
Current Assets
0
1,028
1,163
1,346
1,322
Capital Work in Progress
0
187
102
137
374
Investments
0
32
87
107
77
Other Assets
0
1,038
1,130
1,305
1,319
Total Liabilities
0
2,040
2,244
2,582
2,906
Current Liabilities
0
581
601
694
657
Non Current Liabilities
0
73
85
131
259
Total Equity
0
1,387
1,559
1,757
1,990
Reserve & Surplus
0
1,341
1,513
1,712
1,945
Share Capital
0
0
45
45
45

Cash Flow

Cash Flow
2021
2022
2023
2024
2025
Net Cash Flow
0
78
-71
12
-17
Investing Activities
0
-139
-158
-215
-414
Operating Activities
0
-44
250
216
332
Financing Activities
0
260
-164
10
65

Share Holding

% Holding
Jan 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
44.16 %
45.98 %
45.98 %
46.30 %
46.46 %
46.46 %
46.46 %
46.10 %
44.66 %
44.29 %
43.72 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
8.16 %
8.32 %
7.06 %
7.38 %
8.64 %
7.36 %
7.35 %
DIIs
14.73 %
13.70 %
10.66 %
10.51 %
9.91 %
9.97 %
11.47 %
11.35 %
10.36 %
7.53 %
7.80 %
Government
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
24.66 %
28.35 %
30.23 %
29.13 %
29.74 %
29.71 %
29.57 %
29.45 %
30.39 %
34.10 %
34.43 %
Others
16.44 %
11.96 %
13.12 %
14.04 %
5.72 %
5.52 %
5.43 %
5.71 %
5.94 %
6.71 %
6.69 %
No of Share Holders
3,05,456
2,76,664
2,58,236
2,26,286
2,15,796
2,04,122
1,89,012
1,85,436
1,85,111
1,96,314
1,87,039

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2 3 5
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.46 0.4 0.54

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
22 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
22 Sept 2025 845.95 926.55
15 Sept 2025 DIVIDEND Dividend
₹ 2.50 /share
15 Sept 2025 767.35 926.55
19 Feb 2024 DIVIDEND Dividend
₹ 2.00 /share
16 Feb 2024 550.70 536.20
31 Jul 2024 DIVIDEND Dividend
₹ 1.00 /share
31 Jul 2024 502.45 614.95
07 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
07 Aug 2024 608.50 595.85
28 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Oct 2024 610.40 605.40
05 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Feb 2025 599.00 623.00
14 Feb 2025 DIVIDEND Dividend
₹ 2.50 /share
14 Feb 2025 623.00 733.45
10 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
10 May 2025 754.25 767.35
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Aug 2025 911.20 857.15

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 30, 2025
Reg. 34 (1) Annual Report.Aug 29, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 29, 2025
Notice Of 6Th Annual General MeetingAug 29, 2025
Intimation Regarding 100 Days Campaign - Saksham NiveshakAug 21, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 20, 2025
Record Date For Final Dividend For FY 2024-25Aug 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 13, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 12, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 12, 2025
Financial Results For Quarter Ended June 30 2025Aug 12, 2025
Appointment Of Secretarial AuditorAug 12, 2025
Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Unaudited Financial Results With Limited Review Report For The Quarter Ended June 30 2025Aug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Board Meeting Intimation for Board Meeting Intimation For Unaudited Financial Results For The Quarter Ended June 30 2025.Aug 01, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Closure of Trading WindowJun 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 20, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 12, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 12, 2025
Grant Of Options Under PSOP Scheme 2023May 10, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 10, 2025
Results For The Financial Year Ended 31.03.2025May 10, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Dated 10 May 2025May 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 29, 2025
Board Meeting Intimation for Audited Financial Results For The Year Ended March 31 2025 And Recommendation Of Dividend If Any For The Financial Year Ended March 31 2025.Apr 25, 2025
Intimation Of Change In Email And Website Address Of Registrar And Share Transfer Agent (RTA)Apr 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Announcement under Regulation 30 (LODR)-Joint VentureApr 01, 2025
Closure of Trading WindowMar 20, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 10, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 06, 2025
Record Date For Interim DividendFeb 05, 2025
Corporate Action-Board to consider DividendFeb 05, 2025
Integrated Filing (Financial)Feb 05, 2025
Financial Results For Quarter Ended December 31 2024Feb 05, 2025
Board Meeting Outcome for Financial Results For Quarter Ended December 31 2024Feb 05, 2025

Technical Indicators

RSI(14)
Neutral
62.51
ATR(14)
Less Volatile
29.88
STOCH(9,6)
Overbought
88.43
STOCH RSI(14)
Overbought
96.52
MACD(12,26)
Bullish
9.81
ADX(14)
Weak Trend
15.99
UO(9)
Bearish
53.51
ROC(12)
Uptrend And Accelerating
13.16
WillR(14)
Overbought
-1.25